NCT01337505View on ClinicalTrials.gov

Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

September 30, 2012

Study Completion Date

December 31, 2012

Conditions
Malignant Solid Tumour
Interventions
DRUG

INNO-206

INNO-206 at dosages of 230, 350, and 450 mg/m2 (doxorubicin equivalents of 165, 260, and 325 mg/m2) will be administered as a 30 minute IVI on Day 1 of each cycle.

Trial Locations (1)

90403

Sarcoma Oncology Center, Santa Monica

Sponsors

Lead Sponsor

ImmunityBio, Inc.
All Listed Sponsors
lead

ImmunityBio, Inc.

INDUSTRY

NCT01337505 - Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter